# Rock Springs Capital Management LP 13F Q2 2026: $2 billion

Rock Springs Capital Management LP reported $2 billion in 13F securities across 104 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Revolution Medicines Inc at $207 million, 10.1% of the reported value. Since Q1 2026 it opened 17 new positions and exited 13.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $2,048,808,191
- Positions: 104
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1595725
- Form 13F file number: 028-16048
- CRD number: 168648
- Business address: 650 South Exeter Street Suite 1070, Baltimore, MD 21202
- SEC filing: [0001172661-26-003527](https://www.sec.gov/Archives/edgar/data/1595725/000117266126003527/0001172661-26-003527-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/rock-springs-capital-168648)

## Top 25 holdings by value

The largest of 104 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 1,105,210 | $207 million | -104,255 |
| [Travere Therapeutics Inc](https://specstream.ai/data/institutional-holders/travere-therapeutics-inc-89422g107) | COM | 2,179,069 | $123.8 million | +701,115 |
| [Eli Lilly & Co](https://specstream.ai/data/institutional-holders/eli-lilly-co-532457108) | COM | 98,700 | $118.4 million | No change |
| [Madrigal Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/madrigal-pharmaceuticals-inc-558868105) | COM | 174,999 | $94 million | +4,000 |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 798,145 | $93.4 million | -13,149 |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 692,598 | $76.9 million | +2,850 |
| [Kymera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kymera-therapeutics-inc-501575104) | COM | 453,156 | $52 million | -43,715 |
| [Argenx Se](https://specstream.ai/data/institutional-holders/argenx-se-04016x101) | SPONSORED ADR | 52,750 | $48.9 million | -45,750 |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 168,750 | $45 million | New |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 683,907 | $41.3 million | -79,113 |
| [Scholar Rock HLDG Corp](https://specstream.ai/data/institutional-holders/scholar-rock-hldg-corp-80706p103) | COM | 715,452 | $39.3 million | -24,364 |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 362,150 | $38.6 million | +47,850 |
| [Penumbra Inc](https://specstream.ai/data/institutional-holders/penumbra-inc-70975l107) | COM | 115,750 | $36.5 million | -4,750 |
| [Structure Therapeutics Inc](https://specstream.ai/data/institutional-holders/structure-therapeutics-inc-86366e106) | SPONSORED ADS | 640,317 | $34.4 million | +100 |
| [Ultragenyx Pharmaceutical in](https://specstream.ai/data/institutional-holders/ultragenyx-pharmaceutical-in-90400d108) | COM | 967,855 | $32.3 million | -250,918 |
| [Irhythm Holdings Inc](https://specstream.ai/data/institutional-holders/irhythm-holdings-inc-450056106) | COM | 269,650 | $32.1 million | +7,900 |
| [Intuitive Surgical Inc](https://specstream.ai/data/institutional-holders/intuitive-surgical-inc-46120e602) | COM NEW | 76,460 | $30.4 million | -5,540 |
| [Agilon Health Inc](https://specstream.ai/data/institutional-holders/agilon-health-inc-00857u206) | COM NEW | 262,600 | $28.1 million | +2,600 |
| [Unitedhealth Group Inc](https://specstream.ai/data/institutional-holders/unitedhealth-group-inc-91324p102) | COM | 63,750 | $26.5 million | +10,750 |
| [Celldex Therapeutics Inc New](https://specstream.ai/data/institutional-holders/celldex-therapeutics-inc-new-15117b202) | COM NEW | 699,146 | $26 million | +48,876 |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 1,402,150 | $25.7 million | +298,681 |
| [Neurocrine Biosciences Inc](https://specstream.ai/data/institutional-holders/neurocrine-biosciences-inc-64125c109) | COM | 144,750 | $24.4 million | -5,700 |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 464,625 | $23.6 million | -361,875 |
| [Tenet Healthcare Corp](https://specstream.ai/data/institutional-holders/tenet-healthcare-corp-88033g407) | COM NEW | 125,000 | $23.4 million | No change |
| [Dexcom Inc](https://specstream.ai/data/institutional-holders/dexcom-inc-252131107) | COM | 343,000 | $23.1 million | -12,600 |

## New positions in Q2 2026

17 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 168,750 | $45 million |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 662,918 | $21.8 million |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 575,432 | $21.1 million |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 578,028 | $15.8 million |
| [Omeros Corp](https://specstream.ai/data/institutional-holders/omeros-corp-682143102) | COM | 718,499 | $6.8 million |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 143,187 | $6.7 million |
| [Mobia Med Inc](https://specstream.ai/data/institutional-holders/mobia-med-inc-60705v103) | COMMON STOCK | 418,200 | $5.6 million |
| [Trevi Therapeutics Inc](https://specstream.ai/data/institutional-holders/trevi-therapeutics-inc-89532m101) | COM | 260,000 | $4.8 million |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 42,254 | $3.8 million |
| [Nervgen Pharma Corp](https://specstream.ai/data/institutional-holders/nervgen-pharma-corp-64082x203) | COM | 1,208,231 | $2.5 million |
| [Medtronic PLC](https://specstream.ai/data/institutional-holders/medtronic-plc-g5960l103) | SHS | 30,900 | $2.4 million |
| [Sagimet Biosciences Inc](https://specstream.ai/data/institutional-holders/sagimet-biosciences-inc-786700104) | COM SER A | 250,000 | $1.9 million |
| [Capricor Therapeutics Inc](https://specstream.ai/data/institutional-holders/capricor-therapeutics-inc-14070b309) | COM NEW | 74,448 | $1.8 million |
| [Altimmune Inc](https://specstream.ai/data/institutional-holders/altimmune-inc-02155h200) | COM NEW | 471,465 | $1.4 million |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 65,000 | $1.4 million |
| [Axsome Therapeutics Inc.](https://specstream.ai/data/institutional-holders/axsome-therapeutics-inc-05464t104) | COM | 5,500 | $1.3 million |
| [Glaukos Corp](https://specstream.ai/data/institutional-holders/glaukos-corp-377322102) | COM | 4,750 | $663,860 |

## Positions exited in Q2 2026

13 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Ascendis Pharma A/S | SPONSORED ADR | 194,000 | $44.4 million |
| Arcellx Inc | COMMON STOCK | 169,859 | $19.5 million |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 351,828 | $14 million |
| Soleno Therapeutics Inc | COM | 257,253 | $8.6 million |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/institutional-holders/regeneron-pharmaceuticals-75886f107) | COM | 10,100 | $7.8 million |
| Apellis Pharmaceuticals Inc | COM | 162,750 | $6.5 million |
| Terns Pharmaceuticals Inc | COM | 113,748 | $6 million |
| [SPDR Series Trust](https://specstream.ai/data/institutional-holders/spdr-series-trust-78464a870) | ST STR SP BIOT | 30,000 | $3.8 million |
| [Edwards Lifesciences Corp](https://specstream.ai/data/institutional-holders/edwards-lifesciences-corp-28176e108) | COM | 28,900 | $2.3 million |
| [Acadia Healthcare Company in](https://specstream.ai/data/institutional-holders/acadia-healthcare-company-in-00404a109) | COM | 75,500 | $1.8 million |
| [Jazz Pharmaceuticals PLC](https://specstream.ai/data/institutional-holders/jazz-pharmaceuticals-plc-g50871105) | SHS USD | 5,750 | $1.1 million |
| [Gossamer Bio Inc](https://specstream.ai/data/institutional-holders/gossamer-bio-inc-38341p102) | COM | 1,609,492 | $528,718 |
| Amicus Therapeutic | COM | 21,062 | $304,557 |

## Also on SpecStream

- [Rock Springs Capital Management LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1595725/000117266126003527/0001172661-26-003527-index.htm)
- [Rock Springs Capital Management LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/rock-springs-capital-168648)
- [Largest 13F filers in Maryland](https://specstream.ai/data/institutional-holdings/state/maryland)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Baltimore, Maryland

- [Preschools in Baltimore, Maryland](https://specstream.ai/data/businesses/preschools/baltimore-maryland-united-states)
- [Engineering firms in Baltimore, Maryland](https://specstream.ai/data/businesses/engineering-firms/baltimore-maryland-united-states)
- [Tax preparation firms in Baltimore, Maryland](https://specstream.ai/data/businesses/tax-preparation-firms/baltimore-maryland-united-states)
- [Investment management firms in Baltimore, Maryland](https://specstream.ai/data/businesses/investment-management-firms/baltimore-maryland-united-states)
- [Breweries in Baltimore, Maryland](https://specstream.ai/data/businesses/breweries/baltimore-maryland-united-states)
- [Optometrists in Baltimore, Maryland](https://specstream.ai/data/businesses/optometrists/baltimore-maryland-united-states)
